The company behind an imaging agent meant to identify prostate cancer said it received FDA approval on Thursday for use in patients with suspected metastasis or recurrence.
FDA approves new prostate cancer imaging tool, company says
The company behind an imaging agent meant to identify prostate cancer said it received FDA approval on Thursday for use in patients with suspected metastasis or recurrence.